Sun Pharma, India’s largest drugmaker entered into settlements with certain plaintiffs in the Modafinil Antitrust Litigation matter pending in the United States District Court for the Eastern District of Pennsylvania.
The company didn’t disclose the quantum of the settlement amount. “The settlements extend to all claims brought by the Direct Purchaser Plaintiffs. The terms of the settlements are confidential,” Sun Pharma said in a statement to stock exchanges.
A group of direct purchasers sued Cephalon, Mylan, Teva and Ranbaxy Laboratories in 2006 for so-called “pay-for-delay” settlements in which brand-name drug makers pay their generic counterparts to keep drugs off the market.
Full Content: Money Control
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
